Pfizer Stock Forecast For Long Term

last updated on

Pfizer Stock Forecast For Long Term

Pfizer (Pfe) Stock Forecast For 3 Years

Pfizer (PFE) is a big name in the pharmaceutical space and has a number of products. But according to experts, Pfizer (PFE) will have to face many challenges in the next three years.

In the pharmaceutical industry, exclusive rights are given to drugmakers for a specific period of time. This allows companies like Pfizer to earn massive revenue.

Pfizer To Lose Patents In 2027 And 2028

But once that period is over, anyone can make these drugs as they become non-exclusive. Now, that can be a problem for companies like Pfizer (PFE) as it can also shrink their profits.

If we look at Pfizer (PFE), it will lose the patents for three drugs in 2027 and 2028. All of these are popular drugs, which means they will seriously impact Pfizer's bottom line.

One way to deal with the end of patents is to introduce new drugs. Once again, companies use the revenue they earned from old drugs for the research & development of new ones.

But Pfizer has no big drugs in the pipeline, which makes things tough for it. So, the best thing Pfizer can do right now is to buy another pharma company that has exclusive drugs.

Given Pfizer's market cap of $140 billion, it won't be tough for Pfizer to acquire other companies. So in that regard, there's a way forward for Pfizer to maintain its profitability.

The bottom line is that the next 3 years will be tough for Pfizer stock. But, if we look at the next 5 or 10 years, then Pfizer stock is likely to emerge as a clear winner.

So, if your plan is to buy Pfizer stock and hold it for the long term, then you can consider it. But if your investment timeframe is 3 years or less, then it is better to avoid Pfizer.

The bottom line is that Pfizer stock will face multiple headwinds in the next 3 years. So, it is better to skip it if you are not willing to hold for the long term.

Trending Stories